Last reviewed · How we verify

NCT04116814: IRIR

High Resolution Imaging of Retinal Vessels as a Biomarker of Cardiovascular Disease in Patients With Renal Insufficiency - RI

Status unknown Last updated 10 October 2019
What this trial tests

trial testing wall-to-lumen ratio measurement in Retinal Imaging in 83 participants. Status unknown.

Timeline
21 April 2018
Primary endpoint
29 March 2022
31 March 2022

Quick facts

Lead sponsorRamsay Générale de Santé
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment83
Start date21 April 2018
Primary completion29 March 2022
Estimated completion31 March 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Ramsay Générale de Santé — full company profile →

Who can join

18 and older, any sex, with Retinal Imaging or Cardiovascular Biomarker. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives are to better understand, in the dialysis patient, the relationships between microvascular morphometry and cardiovascular events, survival, arterial hypertension, the pathology responsible for renal failure, the age of dialysis and metabolic parameters. The investigator team also want to better understand the relationship between the diameter of small arteries and parameters such as hypertension, the pathology that causes kidney failure, the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes, BNP, lipid balance, phosphocalcic balance).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ramsay Générale de Santé trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04116814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing